DGAT: Novel Therapeutic Target for Obesity and Type 2 Diabetes Mellitus

Author(s): Angela Subauste, Charles F. Burant.

Journal Name: Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 3 , Issue 4 , 2003


Obesity is currently an exceptionally common problem in humans. The last several years have produced a significant number of breakthroughs in obesity related areas of investigation. Triglycerides are considered the main form of storage of excess calories in fat. A key enzyme in the synthesis of triglycerides is acylCoA: diacylglycerol acyltransferase (DGAT). Recent studies have shown that mice deficient in this enzyme are resistant to diet induced obesity and have increased insulin and leptin sensitivity. These effects suggest that inhibition of DGAT in vivo may be a novel therapeutic target not only for obesity but also for diabetes.

Keywords: dgat, obesity, type 2 diabetes mellitus, acylcoa: diacylglycerol, acyltransferase, free fatty acids

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [263 - 270]
Pages: 8
DOI: 10.2174/1568005310303040263
Price: $58

Article Metrics

PDF: 1